{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:26:20Z","timestamp":1788326780046,"version":"build-2803163510"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000942","name":"Brain Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000942","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021954","name":"Tour de Cure Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001168","name":"Cancer Council Queensland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001168","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007488","name":"Indian Institute of Technology Delhi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007488","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["5\/13\/17\/2020\/NCD-III"],"award-info":[{"award-number":["5\/13\/17\/2020\/NCD-III"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["2019-0154\/CMB\/Adhoc\/BMS"],"award-info":[{"award-number":["2019-0154\/CMB\/Adhoc\/BMS"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004541","name":"Ministry of Education, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008407","name":"The University of Queensland School of Pharmacy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jconrel.2025.113881","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T19:11:13Z","timestamp":1748286673000},"page":"113881","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Gene therapy and nanomedicine for meningioma treatment"],"prefix":"10.1016","volume":"384","author":[{"given":"Deepshikha","family":"Shahdeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taskeen Iqbal","family":"Janjua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Peyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Kulshreshtha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirali","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.113881_bb0005","doi-asserted-by":"crossref","first-page":"e877","DOI":"10.1016\/j.wneu.2021.01.080","article-title":"World Health Organization grade III Meningiomas: a retrospective study at an Academic Medical Center","volume":"149","author":"S\u00e1-Marta","year":"2021","journal-title":"World Neurosurg."},{"issue":"Supplement_5","key":"10.1016\/j.jconrel.2025.113881_bb0010","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113881_bb0015","article-title":"Noncoding RNA landscape and their emerging roles as biomarkers and therapeutic targets in meningioma","volume":"32","author":"Joshi","year":"2024","journal-title":"Molecular Therapy Oncol."},{"key":"10.1016\/j.jconrel.2025.113881_bb0020","doi-asserted-by":"crossref","first-page":"S646","DOI":"10.1016\/j.ibneur.2023.08.1290","article-title":"Nanomedicine and gene therapy to treat glioblastoma","volume":"15","author":"Singh","year":"2023","journal-title":"IBRO Neurosci Rep."},{"key":"10.1016\/j.jconrel.2025.113881_bb0025","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/B978-012088592-3\/50037-2","article-title":"Meningioma","volume":"1","author":"Lamszus","year":"2007","journal-title":"Neurobiol Dis."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113881_bb0030","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.critrevonc.2008.01.010","article-title":"Meningioma","volume":"67","author":"Marosi","year":"2008","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113881_bb0035","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/14737175.2018.1429920","article-title":"Current treatment options for meningioma","volume":"18","author":"Apra","year":"2018","journal-title":"Expert. Rev. Neurother."},{"issue":"18","key":"10.1016\/j.jconrel.2025.113881_bb0040","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1002\/cncr.26625","article-title":"Dental x-rays and risk of meningioma","volume":"118","author":"Claus","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.jconrel.2025.113881_bb0045","doi-asserted-by":"crossref","DOI":"10.1667\/RR3329","article-title":"Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis","volume":"163","author":"Sadetzki","year":"2005","journal-title":"Radiat. Res."},{"issue":"20","key":"10.1016\/j.jconrel.2025.113881_bb0050","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/jnci\/94.20.1555","article-title":"Tumors of the nervous system and pituitary gland associated with atomic bomb radiation exposure","volume":"94","author":"Preston","year":"2002","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113881_bb0055","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s13244-013-0302-4","article-title":"Magnetic resonance imaging of meningiomas: a pictorial review","volume":"5","author":"Watts","year":"2014","journal-title":"Insights Imaging"},{"issue":"2","key":"10.1016\/j.jconrel.2025.113881_bb0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2967\/jnumed.114.147256","article-title":"Somatostatin receptor\u2013targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial","volume":"56","author":"Marincek","year":"2015","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.113881_bb0065","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3390\/biomedicines9030319","article-title":"Meningioma: a review of epidemiology, pathology, diagnosis, treatment, and future directions","volume":"9","author":"Ogasawara","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jconrel.2025.113881_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2016.00040","article-title":"Meningioma genomics: diagnostic, prognostic, and therapeutic applications","volume":"3","author":"Bi","year":"2016","journal-title":"Front. Surg."},{"key":"10.1016\/j.jconrel.2025.113881_bb0075","article-title":"Recent advances in the molecular prognostication of meningiomas","volume":"12","author":"Wang","year":"2023","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113881_bb0080","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.3171\/2013.8.FOCUS13305","article-title":"Current standing and frontiers of gene therapy for meningiomas","volume":"35","author":"De La Garza-Ramos","year":"2013","journal-title":"Neurosurg. Focus"},{"issue":"3","key":"10.1016\/j.jconrel.2025.113881_bb0085","doi-asserted-by":"crossref","DOI":"10.3121\/cmr.4.3.218","article-title":"Gene therapy for cancer treatment: past, present and future","volume":"4","author":"Cross","year":"2006","journal-title":"Clin. Med. Res."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113881_bb0090","first-page":"1039","article-title":"RNAi-mediated abrogation of Cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis","volume":"31","author":"Tummalapalli","year":"2007","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jconrel.2025.113881_bb0095","author":"FDA approves irinotecan liposome for first-line treatment of metastatic pancreatic adenocarcinoma"},{"key":"10.1016\/j.jconrel.2025.113881_bb0100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/B978-0-12-804280-9.00006-8","article-title":"Molecular genetics of meningiomas","volume":"169","author":"Youngblood","year":"2020","journal-title":"Handb. Clin. Neurol."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113881_bb0105","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10014-016-0271-7","article-title":"Genetic landscape of meningioma","volume":"33","author":"Yuzawa","year":"2016","journal-title":"Brain Tumor Pathol."},{"key":"10.1016\/j.jconrel.2025.113881_bb0110","first-page":"21","article-title":"Molecular and translational advances in meningiomas","author":"Suppiah","year":"2019","journal-title":"Neuro Oncol."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113881_bb0115","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3390\/cancers15030980","article-title":"Hormone receptor expression in Meningiomas: a systematic review","volume":"15","author":"Agopiantz","year":"2023","journal-title":"Cancers (Basel)."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113881_bb0120","article-title":"The role of mifepristone in Meningiomas management: a systematic review of the literature","volume":"2015","author":"Cossu","year":"2015","journal-title":"Biomed. Res. Int."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113881_bb0125","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3171\/2016.8.JNS16995","article-title":"Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review","volume":"127","author":"Graillon","year":"2016","journal-title":"J. Neurosurg."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113881_bb0130","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11060-015-1812-3","article-title":"Combined treatment by octreotide and everolimus: octreotide enhances inhibitory effect of everolimus in aggressive meningiomas","volume":"124","author":"Graillon","year":"2015","journal-title":"J. Neurooncol."},{"issue":"33","key":"10.1016\/j.jconrel.2025.113881_bb0135","doi-asserted-by":"crossref","first-page":"55361","DOI":"10.18632\/oncotarget.19517","article-title":"Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro","volume":"8","author":"Graillon","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113881_bb0140","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3171\/2013.8.JNS13535","article-title":"True petroclival meningiomas: results of surgical management","volume":"120","author":"Almefty","year":"2014","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.jconrel.2025.113881_bb0145","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3390\/cancers15020483","article-title":"The role of pharmacotherapy in treatment of meningioma: a systematic review","volume":"15","author":"Shahbandi","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113881_bb0150","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1158\/1078-0432.CCR-22-2085","article-title":"Pharmacological landscape of FDA-approved anticancer drugs reveals sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and carfilzomib in aggressive Meningiomas","volume":"29","author":"Jungwirth","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113881_bb0155","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1158\/1078-0432.CCR-04-2550","article-title":"Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human Meningiomas","volume":"11","author":"Mawrin","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.113881_bb0160","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.3390\/cancers14184448","article-title":"Co-targeting MAP kinase and Pi3K-Akt-mTOR pathways in meningioma: preclinical study of alpelisib and trametinib","volume":"14","author":"Mondielli","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.jconrel.2025.113881_bb0165","doi-asserted-by":"crossref","DOI":"10.1038\/nrneurol.2017.168","article-title":"Advances in meningioma genetics: novel therapeutic opportunities","volume":"14","author":"Preusser","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113881_bb0170","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1007\/s10143-021-01651-w","article-title":"The immunohistochemical expression of SSTR2A is an independent prognostic factor in meningioma","volume":"45","author":"Fodi","year":"2022","journal-title":"Neurosurg. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113881_bb0175","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-009-9948-7","article-title":"Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma","volume":"96","author":"Norden","year":"2010","journal-title":"J. Neurooncol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113881_bb0180","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/nou148","article-title":"Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma","volume":"17","author":"Kaley","year":"2015","journal-title":"Neuro Oncol."},{"issue":"32","key":"10.1016\/j.jconrel.2025.113881_bb0185","doi-asserted-by":"crossref","first-page":"32713","DOI":"10.18632\/oncotarget.5296","article-title":"PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination with Nf2 and Cdkn2ab loss","volume":"6","author":"Peyre","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.jconrel.2025.113881_bb0190","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bpa.12039","article-title":"Miniaturized handheld confocal microscopy identifies focal brain invasion in a mouse model of aggressive meningioma","volume":"23","author":"Peyre","year":"2013","journal-title":"Brain Pathol."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113881_bb0195","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3390\/cancers15030704","article-title":"Intracranial solitary fibrous tumour management: a French multicentre retrospective study","volume":"15","author":"Lottin","year":"2023","journal-title":"Cancers (Basel)."},{"issue":"7","key":"10.1016\/j.jconrel.2025.113881_bb0200","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/neuonc\/noab019","article-title":"Role of 3D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study","volume":"23","author":"Graillon","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.jconrel.2025.113881_bb0205","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.3390\/cancers13153712","article-title":"Mouse models in meningioma research: a systematic review","volume":"13","author":"Boetto","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2025.113881_bb0210","author":"Recursion Pharmaceuticals, Inc."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113881_bb0215","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/lio2.643","article-title":"Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas","volume":"6","author":"Welling","year":"2021","journal-title":"Laryngoscope Investig. Otolaryngol."},{"key":"10.1016\/j.jconrel.2025.113881_bb0220","series-title":"Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma","author":"Study Details","year":"2025"},{"key":"10.1016\/j.jconrel.2025.113881_bb0225","author":"Clinical Trial"},{"key":"10.1016\/j.jconrel.2025.113881_bb0230","author":"Clinical Trial"},{"issue":"11","key":"10.1016\/j.jconrel.2025.113881_bb0235","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3390\/cancers11111633","article-title":"The role of Merlin\/NF2 loss in meningioma biology","volume":"11","author":"Lee","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.jconrel.2025.113881_bb0240","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/cgt.2009.71","article-title":"Imaging and therapy of experimental schwannomas using HSV amplicon vector-encoding apoptotic protein under Schwann cell promoter","volume":"17","author":"Prabhakar","year":"2009","journal-title":"Cancer Gene Therapy"},{"key":"10.1016\/j.jconrel.2025.113881_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneumeth.2021.109141","article-title":"Crispr\/Cas-based modeling of NF2 loss in meningioma cells","volume":"356","author":"Waldt","year":"2021","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.jconrel.2025.113881_bb0250","author":"Clinical Trial"},{"issue":"3","key":"10.1016\/j.jconrel.2025.113881_bb0255","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3390\/ijms25031469","article-title":"Trials and tribulations of MicroRNA therapeutics","volume":"25","author":"Seyhan","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113881_bb0260","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/mps4010010","article-title":"Recent advances in miRNA delivery systems","volume":"4","author":"Dasgupta","year":"2021","journal-title":"Methods Protocols"},{"key":"10.1016\/j.jconrel.2025.113881_bb0265","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/j.wneu.2019.12.182","article-title":"MicroRNA-195 functions as a tumor suppressor by directly targeting fatty acid synthase in malignant meningioma","volume":"136","author":"Song","year":"2020","journal-title":"World Neurosurg."},{"key":"10.1016\/j.jconrel.2025.113881_bb0270","first-page":"10","article-title":"MicroRNA-221\/222 inhibits the radiation-induced invasiveness and promotes the Radiosensitivity of malignant meningioma cells","author":"Zhang","year":"2020","journal-title":"Front. Oncol."},{"issue":"39","key":"10.1016\/j.jconrel.2025.113881_bb0275","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1038\/onc.2012.468","article-title":"miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells","volume":"32","author":"Kliese","year":"2013","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.jconrel.2025.113881_bb0280","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"British J. Cancer"},{"key":"10.1016\/j.jconrel.2025.113881_bb0285","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clineuro.2017.03.016","article-title":"Expression of miRNA-21, miRNA-107, miRNA-137 and miRNA-29b in meningioma","volume":"156","author":"Katar","year":"2017","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113881_bb0290","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tips.2019.10.009","article-title":"Oligonucleotides to the (gene) rescue: FDA approvals 2017\u20132019","volume":"41","author":"R\u00fcger","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"issue":"24","key":"10.1016\/j.jconrel.2025.113881_bb0295","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 Trial of RNAi therapeutic Givosiran for acute intermittent Porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113881_bb0300","doi-asserted-by":"crossref","first-page":"72","DOI":"10.54299\/tmed\/zcno1399","article-title":"Novel drugs approved in 2021-2022","volume":"1","author":"Do","year":"2022","journal-title":"Transformative Med. (T-Med)."},{"issue":"21","key":"10.1016\/j.jconrel.2025.113881_bb0305","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.2217\/fon-2018-0006","article-title":"An overview of meningiomas","volume":"14","author":"Buerki","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.jconrel.2025.113881_bb0310","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jcis.2024.08.074","article-title":"Surface engineering of metal-organic framework nanoparticles-based miRNA carrier: boosting RNA stability, intracellular delivery and synergistic therapy","volume":"677","author":"Jin","year":"2025","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.jconrel.2025.113881_bb0315","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.talanta.2018.02.088","article-title":"Recent biomedical applications of gold nanoparticles: a review","volume":"184","author":"Elahi","year":"2018","journal-title":"Talanta"},{"key":"10.1016\/j.jconrel.2025.113881_bb0320","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3389\/fneur.2020.00945","article-title":"Basis for immunotherapy for treatment of Meningiomas","volume":"11","author":"Garzon-Muvdi","year":"2020","journal-title":"Front. Neurol."},{"issue":"18","key":"10.1016\/j.jconrel.2025.113881_bb0325","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.3390\/cancers15184521","article-title":"Novel advances in treatment of Meningiomas: prognostic and therapeutic implications","volume":"15","author":"Caruso","year":"2023","journal-title":"Cancers (Basel)."},{"issue":"12","key":"10.1016\/j.jconrel.2025.113881_bb0330","first-page":"1911","article-title":"Intraarterial Administration of Peptide Receptor Radionuclide Therapy in patients with advanced meningioma: initial safety and efficacy","volume":"65","author":"Amerein","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.113881_bb0335","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jconrel.2019.10.007","article-title":"MicroRNA delivery through nanoparticles","volume":"313","author":"Lee","year":"2019","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.jconrel.2025.113881_bb0340","first-page":"1019","article-title":"Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in Xenografted aggressive","volume":"17","author":"Pill\u00e9","year":"2006","journal-title":"Breast Cancer"},{"issue":"2\u20133","key":"10.1016\/j.jconrel.2025.113881_bb0345","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0169-409X(96)00453-X","article-title":"The design and development of DaunoXome\u00ae for solid tumor targeting in vivo","volume":"24","author":"Forssen","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"18_suppl","key":"10.1016\/j.jconrel.2025.113881_bb0350","doi-asserted-by":"crossref","first-page":"10707","DOI":"10.1200\/jco.2006.24.18_suppl.10707","article-title":"First-line treatment of metastatic breast cancer with weekly abraxane (nab-paclitaxel: a 130 nm albumin-bound paclitaxel particle): A preliminary analysis of the phase II international oncology network ION-04\u2013012 study","volume":"24","author":"Mirtsching","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113881_bb0355","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00280-012-2042-4","article-title":"Marqibo\u00ae (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine","volume":"71","author":"Silverman","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113881_bb0360","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27041372","article-title":"A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives","volume":"27","author":"Liu","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2025.113881_bb0365","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.addr.2020.06.025","article-title":"Cancer therapy with iron oxide nanoparticles: agents of thermal and immune therapies","volume":"163-164","author":"Soetaert","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113881_bb0370","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1586\/17476348.2015.1081066","article-title":"Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies","volume":"9","author":"Bononi","year":"2015","journal-title":"Expert Rev. Respir. Med."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113881_bb0375","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3171\/2016.10.JNS161636","article-title":"Near-infrared fluorescent image-guided surgery for intracranial meningioma","volume":"128","author":"Lee","year":"2017","journal-title":"J. Neurosurg."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113881_bb0380","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s40478-023-01677-9","article-title":"A novel patient-derived meningioma spheroid model as a tool to study and treat epithelial-to-mesenchymal transition (EMT) in meningiomas","volume":"11","author":"van de Weijer","year":"2023","journal-title":"Acta Neuropathol. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113881_bb0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40478-025-02008-w","article-title":"Establishment of a patient-derived 3D in vitro meningioma model in xeno-free hydrogel for clinical applications","volume":"13","author":"Andersen","year":"2025","journal-title":"Acta Neuropathologica Commun."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925005012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925005012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T04:57:54Z","timestamp":1779512274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925005012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":77,"alternative-id":["S0168365925005012"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113881","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy and nanomedicine for meningioma treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113881","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113881"}}